drugset / Trial / NCT07586709
In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms
NaSingle-groupOpen-labelTreatment
Summary
This study aims to assess the safety profile of in vivo BCMA/GPRC5D-targeted CAR-T cell immunotherapy in patients with relapsed or refractory plasma cell neoplasms.
Timeline
- Start
- 2026-05-09
- Primary completion
- 2029-03-31
- Completion
- 2029-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | In vivo BCMA/GPRC5D Tandem Dual CAR-T cell | Cell therapy | — | — |